Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$5.02 USD
-0.12 (-2.33%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $5.01 -0.01 (-0.20%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Foghorn Therapeutics Inc. has a market cap of $290.56M, which represents its share price of $5.14 multiplied by its outstanding shares number of 56.53M. As a small-cap company, FHTX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
FHTX 5.02 -0.12(-2.33%)
Will FHTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FHTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FHTX
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?
Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know
FHTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing
Other News for FHTX
Is FHTX gaining bullish strength? 200 Day Moving Average Support shows up after slipping 2.33%
Is FHTX gaining bullish strength? Crossed Above 200 Day Moving Average shows up after soaring 7.08%
FHTX Fell Below 200 Day Moving Average on September 18
Foghorn Therapeutics (FHTX) Receives Buy Rating with $10 Target
Foghorn Therapeutics transferred with Buy rating at B. Riley